β¨ Medicines Consent Notices
NEW ZEALAND GAZETTE
No. 27
Product:
Lisinopril
Active Ingredient:
Lisinopril dihydrate equivalent to 10mg lisinopril
Dosage Form:
Tablet
New Zealand Sponsor:
Douglas Pharmaceuticals Limited
Manufacturer:
Delta Limited, Hafnarfjordur, Iceland
Product:
Lisinopril
Active Ingredient:
Lisinopril dihydrate equivalent to 20mg lisinopril
Dosage Form:
Tablet
New Zealand Sponsor:
Douglas Pharmaceuticals Limited
Manufacturer:
Delta Limited, Hafnarfjordur, Iceland
Dated this 12th day of March 2003.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go1807
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Copaxone
Active Ingredient:
Glatiramer acetate 20mg
Dosage Form:
Powder for injection
New Zealand Sponsor:
Aventis Pharma Limited
Manufacturer:
Teva Pharmaceutical Industries Limited, Ikapharm, Kfar Saba, Israel
Note: This consent is valid for two years from 24 May 2003.
Dated this 12th day of March 2003.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go1808
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Temodal
Active Ingredient:
Temozolomide 100mg
Dosage Form:
Capsule
New Zealand Sponsor:
Schering-Plough Animal Health Limited
Manufacturer:
Integrated Therapeutics Group Inc Subsidiary Schering-Plough Corp, Iowa City, Iowa, United States of America
This consent is given subject to the following condition:
- For oncologist only use.
Note: This consent is valid for two years from the date of publication of this notice.
Product:
Temodal
Active Ingredient:
Temozolomide 20mg
Dosage Form:
Capsule
New Zealand Sponsor:
Schering-Plough Animal Health Limited
Manufacturer:
Integrated Therapeutics Group Inc Subsidiary Schering-Plough Corp, Iowa City, Iowa, United States of America
This consent is given subject to the following condition:
- For oncologist only use.
Note: This consent is valid for two years from the date of publication of this notice.
Product:
Temodal
Active Ingredient:
Temozolomide 250mg
Dosage Form:
Capsule
New Zealand Sponsor:
Schering-Plough Animal Health Limited
Manufacturer:
Integrated Therapeutics Group Inc Subsidiary Schering-Plough Corp, Iowa City, Iowa, United States of America
This consent is given subject to the following condition:
- For oncologist only use.
Note: This consent is valid for two years from the date of publication of this notice.
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2003, No 27
Gazette.govt.nz —
NZ Gazette 2003, No 27
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of Lisinopril
π₯ Health & Social Welfare12 March 2003
Medicines Act 1981, Lisinopril, Provisional Consent, Tablet
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Renewal of Provisional Consent for Copaxone
π₯ Health & Social Welfare12 March 2003
Medicines Act 1981, Copaxone, Glatiramer acetate, Renewal of Provisional Consent, Powder for injection
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Provisional Consent for Temodal
π₯ Health & Social Welfare12 March 2003
Medicines Act 1981, Temodal, Temozolomide, Provisional Consent, Capsule, Oncologist use
- G. R. Boyd, Chief Advisor, Safety and Regulation